AMOYTOP(688278)2024-04-22 09:50Financial Performance - The company's operating revenue for Q1 2024 was ¥545,302,286.89, representing a year-over-year increase of 30.05%[4] - Net profit attributable to shareholders for Q1 2024 was ¥128,807,591.33, reflecting a growth of 53.03% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥146,409,781.65, an increase of 42.90% year-over-year[4] - Basic earnings per share for Q1 2024 was ¥0.32, up by 52.38% from the same period last year[4] - Total operating revenue for Q1 2024 reached ¥545,302,286.89, an increase of 30.1% compared to ¥419,307,024.70 in Q1 2023[19] - Net profit for Q1 2024 was ¥128,807,591.33, representing a 52.9% increase from ¥84,173,127.64 in Q1 2023[20] - Earnings per share for Q1 2024 were ¥0.32, compared to ¥0.21 in Q1 2023, reflecting a 52.4% increase[21] - The company reported a total comprehensive income of ¥128,807,591.33 for Q1 2024, compared to ¥84,173,127.64 in Q1 2023, marking a 52.9% increase[21] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥78,663,848.24, showing a significant increase of 260.06%[4] - In Q1 2024, the company generated operating cash inflow of ¥628,928,052.33, a significant increase from ¥387,126,178.14 in Q1 2023, representing a growth of approximately 62.3%[22] - The net cash flow from operating activities for Q1 2024 was ¥78,663,848.24, compared to ¥21,847,454.23 in Q1 2023, indicating a year-over-year increase of about 259.5%[23] - The company reported cash outflow from operating activities totaling ¥550,264,204.09 in Q1 2024, up from ¥365,278,723.91 in Q1 2023, reflecting a rise of approximately 50.6%[23] - The company’s cash and cash equivalents increased by ¥242,422,225.78 in Q1 2024, compared to an increase of ¥219,539,221.52 in Q1 2023, indicating a growth of about 10.4%[24] - The ending balance of cash and cash equivalents reached ¥655,073,171.04 in Q1 2024, up from ¥519,870,257.78 in Q1 2023, representing an increase of approximately 26.0%[24] Assets and Liabilities - The company's total assets at the end of Q1 2024 were ¥2,426,913,277.69, a 3.01% increase from the end of the previous year[5] - The company's total assets reached CNY 2.43 billion, up from CNY 2.36 billion in the previous period, indicating a growth of approximately 3.0%[16] - Total liabilities decreased to ¥421,704,343.64 in Q1 2024 from ¥479,685,751.45 in Q1 2023, a reduction of 12.1%[18] - The company's non-current assets totaled CNY 1.09 billion, an increase from CNY 1.02 billion, representing a growth of about 7.5%[16] - The accounts receivable decreased to CNY 394.76 million from CNY 437.81 million, showing a decline of approximately 9.8%[15] Research and Development - R&D investment totaled ¥55,622,956.59, which decreased by 20.66% year-over-year, and accounted for 10.20% of operating revenue, down by 6.52 percentage points[4][5] - Research and development expenses for Q1 2024 were ¥43,575,928.52, an increase of 15.5% from ¥37,712,423.75 in Q1 2023[19] Shareholder Information - The company reported a total of 7,632 shareholders at the end of the reporting period, with the largest shareholder holding 33.94% of the shares[9] - Total equity attributable to shareholders increased to ¥2,005,208,934.05 in Q1 2024, up 6.9% from ¥1,876,401,342.72 in Q1 2023[18] Charitable Contributions - The company donated CNY 8 million to the "China Chronic Hepatitis B Clinical Cure (Everest) Project," with CNY 200,000 donated during the reporting period[13] - The company has committed to donating up to 30,000 doses of Peginterferon to support hepatitis patients, with 10,000 doses already donated[14] - The company has donated CNY 477.4 million to the "Qihang Project" aimed at exploring treatment options for chronic hepatitis B patients[14] - The company has engaged in various charitable donations, totaling CNY 2.56 million in cash donations to various foundations by the end of the reporting period[13] Operating Costs - Total operating costs for Q1 2024 were ¥379,688,432.09, up 24.7% from ¥304,580,777.32 in Q1 2023[19] - Sales expenses rose to ¥241,910,759.84 in Q1 2024, up 30.0% from ¥186,144,235.35 in Q1 2023[19] - The company paid ¥239,962,364.78 in employee compensation in Q1 2024, which is a significant increase from ¥123,793,401.72 in Q1 2023, reflecting a growth of about 93.9%[23] - Tax payments in Q1 2024 amounted to ¥56,272,206.36, compared to ¥24,146,198.04 in Q1 2023, indicating an increase of approximately 133.4%[23] - The company’s cash outflow related to other operating activities was ¥207,741,927.92 in Q1 2024, slightly up from ¥196,536,352.53 in Q1 2023, showing an increase of about 5.4%[23] Product Recognition - The significant increase in operating revenue was attributed to the growing recognition of the product Paigebin among experts and patients, leading to sustained sales growth[8]